SCShu-Bo Chen

Shu-Bo Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shu-Bo Chen has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaochong Zhang

    Department of Urology, Xingtai People's Hospital, Xingtai, Hebei Province, 054001, China; Hebei Provincial Key Laboratory of Portal Hypertension and Cirrhosis, Xingtai, Hebei Province, 054031, China

    4 shared publications
  • Tian Hua

    Department of Gynecology, Affiliated Xingtai People Hospital of Hebei Medical University, Xingtai, China

    3 shared publications
  • Xiao-Chong Zhang

    Department of Oncology, Affiliated Xingtai People Hospital of Hebei Medical University, Xingtai, People’s Republic of China

    3 shared publications
  • Chao Tan

    Department of Urology, Xingtai People's Hospital, Xingtai, Hebei Province, 054001, China; Hebei Provincial Key Laboratory of Portal Hypertension and Cirrhosis, Xingtai, Hebei Province, 054031, China

    2 shared publications
  • Deng-Xiang Liu

    Department of Oncology, Affiliated Xingtai People Hospital of Hebei Medical University, Xingtai, People’s Republic of China

    2 shared publications
  • Deng-Xiang Liu

    Department of oncology, Affiliated Xingtai People Hospital of Hebei Medial University 399 Shunde Road, Xingtai 054001, China

    2 shared publications

Latest Publications

  • Open Access

    Prognostic value of the inflammatory prognostic index for postoperative recurrence in non-muscle-invasive bladder cancer

    by GengXu Li, Chao Tan, JunLi Wei, ShuBo Chen

    Background: To evaluate the prognostic value of the inflammatory prognostic index (IPI) for recurrence after transurethral resection of bladder tumour (TURBT) in non-muscle-invasive bladder cancer (NMIBC), and to compare its discriminatory performance with that of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR). Methods: This retrospective study included 123 patients who underwent TURBT for primary NMIBC. The primary analysis evaluated IPI as a continuous variable. Optimal cut-off values were determined by receiver operating characteristic (ROC) curve analysis, recurrence-free survival (RFS) was characterised by Kaplan–Meier estimation, and independent predictors were identified by Cox proportional hazards regression. Bootstrap internal validation (B = 1000) was applied to quantify overfitting and assess cut-off stability. Results: During a median follow-up of 36 months, 44 patients (35.8%) developed disease recurrence. Among the markers tested, IPI showed the largest area under the curve (AUC = 0.790, 95% CI 0.705–0.874) and performed better than NLR (AUC = 0.613), PLR (AUC = 0.523, 95% CI 0.418–0.629), and LMR (AUC = 0.624). When analysed as a continuous variable, each 0.1‑unit increase in IPI was associated with a 12% higher recurrence risk (HR 1.12, 95% CI 1.07–1.18, P < 0.001). For clinical interpretability, the optimal IPI cut-off was 0.223. In multivariable analysis, IPI ≥ 0.223 (HR 5.574, 95% CI 2.583–12.029, P < 0.001) and diabetes mellitus (HR 2.853, 95% CI 1.279–6.366, P = 0.010) were independently associated with recurrence. IPI remained significant after adjustment for either pathological grade or EAU risk group. A pre‑specified Fine–Gray competing‑risks sensitivity simulation gave similar results, suggesting that the association was not driven by overestimation of recurrence in the presence of hypothetical competing non‑cancer mortality (subdistribution HR 5.91, 95% CI 2.87–12.19; P < 0.001). Bootstrap validation suggested limited overfitting (bias-corrected C-statistic 0.790; optimism 0.020), a stable cut-off (bootstrap median 0.227, 95% CI 0.084–0.617), and good calibration (bias-corrected calibration slope 0.86, Brier score 0.091). Conclusions: Preoperative IPI, analysed primarily as a continuous variable, was an independent predictor of recurrence after TURBT in patients with NMIBC, with each 0.1‑unit increase associated with a 12% higher recurrence risk. It showed better discriminatory accuracy than NLR, PLR, and LMR and may be a practical, low‑cost adjunct for risk stratification and individualized postoperative surveillance; the dichotomised threshold reported here is cohort‑specific and requires external validation.

  • Open Access

    Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq

    by Tian Hua, Deng-Xiang Liu, Xiao-Chong Zhang, Shao-Teng Li, Jian-Lei Wu, Qun Zhao, Shu-Bo Chen

    Ovarian cancer (OC) was the fifth leading cause of cancer death and the deadliest gynecological cancer in women. This was largely attributed to its late diagnosis, high therapeutic resistance, and a dearth of effective treatments. Clinical and preclinical studies have revealed that tumor-infiltrating CD8+T cells often lost their effector function, the dysfunctional state of CD8+T cells was known as exhaustion. Our objective was to identify genes associated with exhausted CD8+T cells (CD8TEXGs) and their prognostic significance in OC. We downloaded the RNA-seq and clinical data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. CD8TEXGs were initially identified from single-cell RNA-seq (scRNA-seq) datasets, then univariate Cox regression, the least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression were utilized to calculate risk score and to develop the CD8TEXGs risk signature. Kaplan–Meier analysis, univariate Cox regression, multivariate Cox regression, time-dependent receiver operating characteristics (ROC), nomogram, and calibration were conducted to verify and evaluate the risk signature. Gene set enrichment analyses (GSEA) in the risk groups were used to figure out the closely correlated pathways with the risk group. The role of risk score has been further explored in the homologous recombination repair deficiency (HRD), BRAC1/2 gene mutations and tumor mutation burden (TMB). A risk signature with 4 CD8TEXGs in OC was finally built in the TCGA database and further validated in large GEO cohorts. The signature also demonstrated broad applicability across various types of cancer in the pan-cancer analysis. The high-risk score was significantly associated with a worse prognosis and the risk score was proven to be an independent prognostic biomarker. The 1-, 3-, and 5-years ROC values, nomogram, calibration, and comparison with the previously published models confirmed the excellent prediction power of this model. The low-risk group patients tended to exhibit a higher HRD score, BRCA1/2 gene mutation ratio and TMB. The low-risk group patients were more sensitive to Poly-ADP-ribose polymerase inhibitors (PARPi). Our findings of the prognostic value of CD8TEXGs in prognosis and drug response provided valuable insights into the molecular mechanisms and clinical management of OC.


  • Integrin β4 Regulates Cell Migration of Lung Adenocarcinoma Through FAK Signaling

    by Shusen Zhang, Chengyu Liu, Dengxiang Liu, Xuecong Ning, Hui Li, Xiaochong Zhang, Yuanyuan Lu, Ping Zhang, Shubo Chen, Zhigang Cai

    The role of the integrin family in malignancy has received increasing attention. Many studies have confirmed that ITGB4 could activate multiple signal pathways and promote cell migration in various cancers. However, the regulatory role of integrin β4 (ITGB4) in lung adenocarcinoma (LUAD) is still unclear. Examination of the expression or survival analysis of ITGB4 in cells, pathological samples, and bioinformatics lung adenocarcinoma databases showed ITGB4 was highly expressed in LUAD and significantly associated with poor prognosis. Small interfering RNA and plasmids were performed to investigate the effect of changes in ITGB4 expression on lung adenocarcinoma. Focal adhesion kinase (FAK) inhibitor defactinib was used to further explore the molecular mechanism of ITGB4. The results showed depletion of ITGB4 inhibited migration and activation of FAK signaling pathways in lung adenocarcinoma cells. Moreover, increased ITGB4 expression activated FAK signaling and promoted cell migration, which can be reversed by defactinib. In addition, ITGB4 could interact with FAK in lung adenocarcinoma cells. ITGB4 may promote cell migration of lung adenocarcinoma through FAK signaling pathway and has the potential to be a biomarker for lung adenocarcinoma. Graphical Abstract Integrin β4 (ITGB4), Focal adhesion kinase (FAK), The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression and Broad Institute Cancer Cell Line Encyclopedia (CCLE), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and Co- immunoprecipitation (Co-IP).


  • Open Access

    Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

    by Jitao Wang, Tianlei Zheng, Yong Liao, Shi Geng, Jinlong Li, Zhanguo Zhang, Dong Shang, Chengyu Liu, Peng Yu, Yifei Huang, et al.

    Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

  • Open Access

    CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer

    by Tian Hua, Deng-Xiang Liu, Xiao-Chong Zhang, Shao-Teng Li, Peng Yan, Qun Zhao, Shu-Bo Chen

    Introduction: It is believed that ovarian cancer (OC) is the most deadly form of gynecological cancer despite its infrequent occurrence, which makes it one of the most salient public health concerns. Clinical and preclinical studies have revealed that intratumoral CD4+ T cells possess cytotoxic capabilities and were capable of directly killing cancer cells. This study aimed to identify the CD4+ conventional T cells-related genes (CD4TGs) with respect to the prognosis in OC.Methods: We obtained the transcriptome and clinical data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. CD4TGs were first identified from single-cell datasets, then univariate Cox regression was used to screen prognosis-related genes, LASSO was conducted to remove genes with coefficient zero, and multivariate Cox regression was used to calculate riskscore and to construct the CD4TGs risk signature. Kaplan-Meier analysis, univariate Cox regression, multivariate Cox regression, time-dependent receiver operating characteristics (ROC), decision curve analysis (DCA), nomogram, and calibration were made to verify and evaluate the risk signature. Gene set enrichment analyses (GSEA) in risk groups were conducted to explore the tightly correlated pathways with the risk group. The role of riskscore has been further explored in the tumor microenvironment (TME), immunotherapy, and chemotherapy. A risk signature with 11 CD4TGs in OC was finally established in the TCGA database and furtherly validated in several GEO cohorts.Results: High riskscore was significantly associated with a poorer prognosis and proven to be an independent prognostic biomarker by multivariate Cox regression. The 1-, 3-, and 5-year ROC values, DCA curve, nomogram, and calibration results confirmed the excellent prediction power of this model. Compared with the reported risk models, our model showed better performance. The patients were grouped into high-risk and low-risk subgroups according to the riskscore by the median value. The low-risk group patients tended to exhibit a higher immune infiltration, immune-related gene expression and were more sensitive to immunotherapy and chemotherapy.Discussion: Collectively, our findings of the prognostic value of CD4TGs in prognosis and immune response, provided valuable insights into the molecular mechanisms and clinical management of OC.


  • A Signature Constructed Based on the Integrin Family Predicts Prognosis and Correlates with the Tumor Microenvironment of Patients with Lung Adenocarcinoma

    by Shusen Zhang, Dengxiang Liu, Xuecong Ning, Xiaochong Zhang, Yuanyuan Lu, Yang Zhang, Aimin Li, Zhiguo Gao, Zhihua Wang, Xiaoling Zhao, et al.

    As an important element in regulating tumor microenvironment, integrin plays a key role in tumor progression. This study aimed to establish prognostic signatures to predict the overall survival and identify the immune landscape of patients with lung adenocarcinoma based on integrins. The Cancer Genome Atlas-Lung adenocarcinoma (TCGA-LUAD) and Gene Expression Omnibus data sets were used to obtain information on mRNA levels and clinical factors (GSE72094). The least absolute shrinkage and selection operator (LASSO) model was used to create a prediction model that included six integrin genes. The nomogram, risk score, and time-dependent receiver operating characteristic analysis all revealed that the signatures had a good prognostic value. The gene signatures may be linked to carcinogenesis and TME, according to a gene set enrichment analysis. The immunological and stromal scores were computed using the ESTIMATE algorithm, and the data revealed, the low-risk group had a higher score. We discovered that the B lymphocytes, plasma, CD4+ T, dendritic, and mast cells were much higher in the group with low-risk using the CiberSort. Inflammatory processes and several HLA family genes were upregulated in the low-risk group. The low-risk group with a better prognosis is more sensitive to immune checkpoint inhibitor medication, according to Immunophenoscore (IPS) research. We found that the patients in the high-risk group were more susceptible to chemotherapy than other group patients, according to the prophetic algorithm. The gene signatures could accurately predict the prognosis, identify the immune status of patients with lung adenocarcinoma, and provide guidance for therapy.


  • Open Access

    Deciphering the expression patterns of homologous recombination-related lncRNAs identifies new molecular subtypes and emerging therapeutic opportunities in epithelial ovarian cancer

    by Tian Hua, Xiao-Chong Zhang, Wei Wang, Yun-Jie Tian, Shu-Bo Chen

    Epithelial ovarian cancer (EOC) is the leading killer among women with gynecologic malignancies. Homologous recombination deficiency (HRD) has attracted increasing attention due to its significant implication in the prediction of prognosis and response to treatments. In addition to the germline and somatic mutations of homologous recombination (HR) repair genes, to widely and deeply understand the molecular characteristics of HRD, we sought to screen the long non-coding RNAs (lncRNAs) with regard to HR repair genes and to establish a prognostic risk model for EOC. Herein, we retrieved the transcriptome data from the Genotype-Tissue Expression Project (GTEx) and The Cancer Genome Atlas (TCGA) databases. HR-related lncRNAs (HRRlncRNAs) associated with prognosis were identified by co-expression and univariate Cox regression analyses. The least absolute shrinkage and selection operator (LASSO) and multivariate stepwise Cox regression were performed to construct an HRRlncRNA risk model containing AC138904.1, AP001001.1, AL603832.1, AC138932.1, and AC040169.1. Next, Kaplan−Meier analysis, time-dependent receiver operating characteristics (ROC), nomogram, calibration, and DCA curves were made to verify and evaluate the model. Gene set enrichment analysis (GSEA), immune analysis, and prediction of the half-maximal inhibitory concentration (IC50) in the risk groups were also analyzed. The calibration plots showed a good concordance with the prognosis prediction. ROCs of 1-, 3-, and 5-year survival confirmed the well-predictive efficacy of this model in EOC. The risk score was used to divide the patients into high-risk and low-risk subgroups. The low-risk group patients tended to exhibit a lower immune infiltration status and a higher HRD score. Furthermore, consensus clustering analysis was employed to divide patients with EOC into three clusters based on the expression of the five HRRlncRNAs, which exhibited a significant difference in checkpoints’ expression levels and the tumor microenvironment (TME) status. Taken together, the results of this project supported that the five HRRlncRNA models might function as a biomarker and prognostic indicator with respect to predicting the PARP inhibitor and immune treatment in EOC.


    • 15 August 2022
      • Vol. 14  (8) , 5883-5895

    Development and validation of AKI prediction model in postoperative critically ill patients: a multicenter cohort study

    by Yu Zhang, Xiaochong Zhang, Xiuming Xi, Wei Dong, Zongmao Zhao, Shubo Chen

    Background: Acute kidney injury (AKI) is a common complication, especially among postoperative critically ill patients. Early identification of AKI is essential for reducing mortality. Methods: Multicenter data were used to develop an AKI prediction model for critically ill postoperative patients. A total of 1731 patients admitted to intensive care units (ICUs) were divided into a development set (n=1196) and a validation set (n=535) according to the principle of 7:3 randomization. Multivariate logistic regression analysis was performed on the predictors identified by univariate analysis, and a nomogram was created based on the predictors. The area under the receiver operating characteristic curve (AUROC) was used to assess the discrimination of the model. Calibration curves were generated, and the Hosmer-Lemeshow (HL) goodness of fit test was carried out. Decision curve analysis (DCA) was performed to assess the net clinical benefit. Results: The final model included 7 predictors: age, emergency surgery, abnormal basal creatinine level (BCr), chronic kidney disease (CKD), use of nephrotoxic drugs, diuretic use, and the Sequential Organ Failure Assessment (SOFA) score. A nomogram was drawn based on the predictors. The AUROC of the model in the development set was 0.725 (95% confidence interval (CI): 0.696-0.754). In the validation set, the AUROC was 0.706 (95% CI: 0.656-0.744). The model showed good discrimination (> 70%) in both sets, and the HL test indicated that the model fit was good (P > 0.05). DCA showed that our model is clinically useful. Conclusion: The novel prediction model can be used to identify high-risk postoperative patients and provide a scientific and effective basis for clinicians to identify AKI early with a nomogram.


  • Open Access

    Tetramethylpyrazine inhibits proliferation of colon cancer cells in vitro

    by Hua Li, Yan-Xu Hou, Yu Yang, Qing-Qiang He, Tian-Hua Gao, Xiao-Feng Zhao, Zhi-Bin Huo, Shu-Bo Chen, Deng-Xiang Liu

    Colon cancer is one of the most common malignancies worldwide, and chemotherapy is a widely used strategy in colon cancer clinical therapy. However, chemotherapy resistance is a major cause of disease recurrence and progression in colon cancer, and thus novel drugs for treatment are urgently needed. Tetramethylpyrazine (TMP), a component of the traditional Chinese medicine Chuanxiong Hort, has been proven to exhibit a beneficial effect in tumors. To investigate the potential anticancer activity of TMP in colon cancer and its underlying mechanisms. Colon cancer cells were incubated with different concentrations of TMP. Cell viability was evaluated by crystal violet staining assay and cell counting kit-8 assay, and cell apoptosis and cell cycle were assessed by flow cytometry. TMP significantly inhibited the proliferation of colon cancer cells in a dose- and time-dependent manner. In addition, flow cytometry revealed that TMP induced cell cycle arrest at the G0/G1 phase. TMP treatment caused early stage apoptosis in SW480 cells, whereas it caused late stage apoptosis in HCT116 cells. Our studies demonstrated that TMP inhibits the proliferation of colon cancer cells in a dose- and time-dependent manner by inducing apoptosis and arresting the cell cycle at the G0/G1 phase. Our findings suggest that TMP might serve as a potential novel therapeutic drug in the treatment of human colon cancer.